Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

More measles cases have been reported in Washington state. Officials in Seattle-King County yesterday reported two measles ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...

Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...